Skip to main content

Table 1 Demographic features and clinical characteristics of 362 DMD/BMD patients and carriers

From: Brain natriuretic peptide is not predictive of dilated cardiomyopathy in Becker and Duchenne muscular dystrophy patients and carriers

  DMD BMD Functionally symptomatic carrier DMD Functionally asymptomatic carrier DMD Functionally symptomatic carrier BMD Functionally asymptomatic carrier BMD
n 55 88 10 130 4 75
Median age (yr) (range) 12 (8–44) 30 (8–59) 56 (27–69) 44 (8–68) 47 (22–64) 44 (16–72)
Median disease duration (yr) (range) 10 (4–41) 20 (1–52) 10 (0–36) na 26 (7–44) na
Median vital capacity (%) (range) 52 (14–84) 88 (18–161) 87 (69–125) 106 (61–203) 115 (41–122) 108 (61–166)
Median diastolic blood pressure (mmHg) (range) 66 (44–87) 76 (48–112) 82 (67–99) 83 (56–116) 77 (73–90) 77 (60–108)
Hypertension + 2 (4%) 26 (30%) 7 (70%) 54 (42%) 1 (25%) 23 (31%)
Wheelchair bound 34 (62%) 12 (14%) 0% na 0% na
Treatment # 3 (6%) 17 (19%) 3 (30%) 14 (11%) 1 (25%) 4 (5%)
Any Symptom CHF* 6 (11%) 15 (17%) 7 (70%) 30 (23%) 3 (75%) 19 (25%)
Obesity § 0 5 (6%) 6 (30%) 19 (16%) 1 (25%) 9 (13%)
  1. #Treatment: percentage of persons receiving medication including beta-blockers, diuretics, Angiotensin Converting Enzyme-inhibitors (ACE-inhibitors) or Angiotensin II type-1 inhibitors (AT-1-inhibitors).
  2. *Symptoms of CHF: percentage with any symptom of cardiac heart failure (CHF) like nocturia, orthopnea, exercise induced dyspnoea, chest pain or dizziness.
  3. +Hypertension: blood pressure higher than 90 mmHg diastolic or 140 mmHg systolic.
  4. §Obesity: Body Mass Index >30.
  5. na not applicable.